Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses

    Freespira, which makes a digital treatment for panic and post-traumatic stress disorders, expects to break even by the end of 2025.
    by Mario Aguilar Jun 18, 2024 1 minute
    Source: Courtesy Freespira

    Many digital health companies have crashed and burned after promising investors speedy adoption and huge revenues. Freespira, maker of a software- and

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Rejection Of An AbbVie Parkinson’s Drug, PBM Markups On Mail Order, And More
    The FDA declined to approve an AbbVie therapy for patients with Parkinson's disease due to problems at a third-party manufacturer.
    STAT1 min read
    STAT+: How Controversial Was The Decision By FDA’s Peter Marks To Approve Sarepta’s Gene Therapy? Check Its Footnotes
    The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks even more surprising on a close examination.
    STAT1 min read
    Moderna Receives $176 Million From BARDA For MRNA Influenza Vaccines
    Moderna will receive $176 million from HHS' BARDA to accelerate development of mRNA-based pandemic influenza vaccines, the company said Tuesday.

    Related Books & Audiobooks